The latter finding suggests that combination therapies geared at targeted both EGFR and HER2 (i.e., trastuzumab + cetuximab or lapatinib) may be beneficial in CRC that display amplification of both genes. This evidence concerns the gene ERBB2 and colorectal carcinoma.